Insurers still overlook breast cancer screening

Article

This year's annual report from the National Committee for Quality Assurance showed a mixed bag of good and bad news, reported Managed Care (11/2005). Of the 289 commercial health plans that reported data to the NCQA, the average performance showed improvements in 18 of 22 clinical measures.

This year's annual report from the National Committee for Quality Assurance showed a mixed bag of good and bad news, reported Managed Care (11/2005). Of the 289 commercial health plans that reported data to the NCQA, the average performance showed improvements in 18 of 22 clinical measures. First the bad news: The average performance of the health plans worsened with respect to breast cancer screening. On the other hand, the clinical measures that did show improvement included beta-blocker treatment after a heart attack, comprehensive diabetes care, cholesterol management control, high blood pressure control, and childhood immunization status.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Subscribe Now!
Recent Videos
Thomas McElrath, MD, PhD, highlights limitations of current preeclampsia guidelines | Image Credit: physiciandirectory.brighamandwomens.org.
Jane Varney, MD, discusses how a low FODMAP diet mediates gut symptoms caused by endometriosis | Image Credit: lens.monash.edu.
Ousseny Zerbo, PhD, highlights benefits of influenza vaccination during pregnancy | Image Credit: divisionofresearch.kaiserpermanente.org.
Michael Ussher, PhD, highlights the benefits of vaping over smoking in pregnancy | Image Credit: sgul.ac.uk.
Neal Barnard, MD, FACC, highlights AMA's new breast cancer prevention guidelines | Image Credit: pcrm.org.
Related Content
Experts urge FDA to revise boxed warnings on hormone therapies for menopause | Image credit: Contemporary OB/GYN

Experts urge FDA to revise boxed warnings on hormone therapies for menopause

Morgan Ebert, Managing Editor
July 18th 2025
Article

Experts urge the FDA to update outdated warnings on menopausal hormone therapies, emphasizing the safety and benefits of low-dose vaginal estrogen.

Read More

Pap Talk S4E15: MIRA surgical system for hysterectomy with Jean Dubuisson, MD, PhD

Pap Talk S4E15: MIRA surgical system for hysterectomy with Jean Dubuisson, MD, PhD

Celeste Krewson, Assistant Editor
December 31st 2024
Podcast

In this episode of Pap Talk, Jean Dubuisson, MD, PhD, discusses the first successful hysterectomy performed using the MIRA surgical system.

Listen

Distressed birth linked to long-term physical and mental health risks | Image Credit: © Katecat - © Katecat - stock.adobe.com.

Distressed birth linked to long-term physical and mental health risks

Celeste Krewson, Assistant Editor
July 18th 2025
Article

Infants born preterm or with complications face higher risks of chronic conditions in adulthood, highlighting policy and health care needs.

Read More

Site Logo

How Individually Identifying More HPV Types Enables Better Patient Management and More Precise Care

September 29th 2023
Podcast

Listen

DM199 shows promise in phase 2 trial for treating preeclampsia | Image Credit: © Egor - © Egor - stock.adobe.com.

DM199 shows promise in phase 2 trial for treating preeclampsia

Celeste Krewson, Assistant Editor
July 17th 2025
Article

DiaMedica Therapeutics' investigational therapy DM199 significantly reduced blood pressure and improved uterine blood flow in patients with preeclampsia, with a favorable safety profile.

Read More

Tirzepatide plus hormone therapy boosts weight loss in menopausal women | Image Credit: © Mike Kemp/Blend Images - © Mike Kemp/Blend Images - stock.adobe.com.

Tirzepatide plus hormone therapy boosts weight loss in menopausal women

Celeste Krewson, Assistant Editor
July 17th 2025
Article

Tirzepatide and menopause hormone therapy may significantly enhance weight loss and health outcomes in postmenopausal women.

Read More

© 2025 MJH Life Sciences

All rights reserved.